- Home
- SPFI vs PHAR Comparison
SPFI vs PHAR Comparison
Compare SPFI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- PHAR
- Stock Information
- Founded
- SPFI 1941
- PHAR 1988
- Country
- SPFI United States
- PHAR Netherlands
- Employees
- SPFI N/A
- PHAR N/A
- Industry
- SPFI Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- PHAR Health Care
- Exchange
- SPFI Nasdaq
- PHAR Nasdaq
- Market Cap
- SPFI 647.7M
- PHAR 627.5M
- IPO Year
- SPFI 2019
- PHAR N/A
- Fundamental
- Price
- SPFI $35.83
- PHAR $9.10
- Analyst Decision
- SPFI Buy
- PHAR Strong Buy
- Analyst Count
- SPFI 2
- PHAR 3
- Target Price
- SPFI $33.50
- PHAR $27.00
- AVG Volume (30 Days)
- SPFI 35.9K
- PHAR 7.3K
- Earning Date
- SPFI 01-24-2025
- PHAR 10-24-2024
- Dividend Yield
- SPFI 1.68%
- PHAR N/A
- EPS Growth
- SPFI N/A
- PHAR N/A
- EPS
- SPFI 2.56
- PHAR N/A
- Revenue
- SPFI $183,911,000.00
- PHAR $285,745,000.00
- Revenue This Year
- SPFI N/A
- PHAR $20.89
- Revenue Next Year
- SPFI $6.18
- PHAR $11.15
- P/E Ratio
- SPFI $13.98
- PHAR N/A
- Revenue Growth
- SPFI N/A
- PHAR 30.64
- 52 Week Low
- SPFI $24.05
- PHAR $6.65
- 52 Week High
- SPFI $40.91
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- SPFI 39.80
- PHAR 61.21
- Support Level
- SPFI $38.55
- PHAR $8.24
- Resistance Level
- SPFI $39.49
- PHAR $9.59
- Average True Range (ATR)
- SPFI 1.51
- PHAR 0.35
- MACD
- SPFI -0.51
- PHAR 0.10
- Stochastic Oscillator
- SPFI 50.00
- PHAR 76.89
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has two reportable segments: banking and insurance.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.